These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 24476391)

  • 1. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.
    Kakarla R; Liu J; Naduthambi D; Chang W; Mosley RT; Bao D; Steuer HM; Keilman M; Bansal S; Lam AM; Seibel W; Neilson S; Furman PA; Sofia MJ
    J Med Chem; 2014 Mar; 57(5):2136-60. PubMed ID: 24476391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B.
    Wang Z; Chen X; Wu C; Xu H; Liu H
    Curr Top Med Chem; 2016; 16(12):1362-71. PubMed ID: 26585935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3-
    Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY
    Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New potent biaryl sulfate-based hepatitis C virus inhibitors.
    You Y; Kim HS; Bae IH; Lee SG; Jee MH; Keum G; Jang SK; Kim BM
    Eur J Med Chem; 2017 Jan; 125():87-100. PubMed ID: 27657807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C replication inhibitors that target the viral NS4B protein.
    Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
    J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
    Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
    Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
    Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.
    Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
    Belema M; Nguyen VN; St Laurent DR; Lopez OD; Qiu Y; Good AC; Nower PT; Valera L; O'Boyle DR; Sun JH; Liu M; Fridell RA; Lemm JA; Gao M; Knipe JO; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4428-35. PubMed ID: 23803586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
    Chen G; Ren H; Zhang N; Lennox W; Turpoff A; Paget S; Li C; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Colacino J; Lahser F; Zhao X; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2015 Feb; 25(4):781-6. PubMed ID: 25613678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.
    Ruebsam F; Murphy DE; Tran CV; Li LS; Zhao J; Dragovich PS; McGuire HM; Xiang AX; Sun Z; Ayida BK; Blazel JK; Kim SH; Zhou Y; Han Q; Kissinger CR; Webber SE; Showalter RE; Shah AM; Tsan M; Patel RA; Thompson PA; Lebrun LA; Hou HJ; Kamran R; Sergeeva MV; Bartkowski DM; Nolan TG; Norris DA; Khandurina J; Brooks J; Okamoto E; Kirkovsky L
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6404-12. PubMed ID: 19818610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent HCV NS4B inhibitors with activity against multiple genotypes.
    Phillips B; Cai R; Delaney W; Du Z; Ji M; Jin H; Lee J; Li J; Niedziela-Majka A; Mish M; Pyun HJ; Saugier J; Tirunagari N; Wang J; Yang H; Wu Q; Sheng C; Zonte C
    J Med Chem; 2014 Mar; 57(5):2161-6. PubMed ID: 24512292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
    Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
    Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.